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The primary toll-like receptor (TLR)-mediated immune cell response pathway common 
for all TLRs is MyD88-dependent activation of NF-κB, a seminal transcription factor for 
many chemokines and cytokines. Remarkably, anucleate platelets express the NF-κB 
machinery, whose role in platelets remains poorly understood. Here, we investigated 
the contribution of NF-κB in the release of cytokines and serotonin by human platelets, 
following selective stimulation of TLR2 and protease activated receptor 1 (PAR1), a 
classical and non-classical pattern-recognition receptor, respectively, able to participate 
to the innate immune system. We discovered that platelet PAR1 activation drives the 
process of NF-κB phosphorylation, in contrast to TLR2 activation, which induces a 
slower phosphorylation process. Conversely, platelet PAR1 and TLR2 activation induces 
similar ERK1/2, p38, and AKT phosphorylation. Moreover, we found that engagement of 
platelet TLR2 with its ligand, Pam3CSK4, significantly increases the release of sCD62P, 
RANTES, and sCD40L; this effect was attenuated by incubating platelets with a blocking 
anti-TLR2 antibody. This effect appeared selective since no modulation of serotonin 
secretion was observed following platelet TLR2 activation. Platelet release of sCD62P, 
RANTES, and sCD40L following TLR2 or PAR1 triggering was abolished in the presence 
of the NF-κB inhibitor Bay11-7082, while serotonin release following PAR1 activation 
was significantly decreased. These new findings support the concept that NF-κB is an 
important player in platelet immunoregulations and functions.
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inTrODUcTiOn
Besides their central role in hemostasis, platelets have now entered the field of immunity as inflam-
matory cells (1–5). Initial studies reported the first evidence of the presence of toll-like receptors 
(TLRs) on human platelets and showed that their level significantly increases following activation (6, 
7). We also found that stored platelets contain molecules with known immunomodulatory roles and 
differentially secrete them upon storage in blood banking conditions (8–11). One of the best-studied 
2Damien et al. Platelet TLR2 Activation and Signaling Pathway
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 85
platelet TLRs is TLR4. Recent studies by our group (12) and oth-
ers (13, 14) support the idea that platelets are able to distinguish 
between membrane signaling molecules and can for instance, 
adapt their secretion to specific signals sensed via TLR4. Recently, 
we have shown that soluble (s)CD14 from plasma contributes to 
LPS/TLR4 signaling in platelets to allow the potent release of 
sCD40L, thereby elucidating the mechanism of LPS-induced 
platelet responses and providing new insights for reducing LPS 
toxicity in the circulation (15).
Toll-like receptor 2 is also expressed in platelets and recog-
nizes components of Gram-positive bacteria. In cooperation with 
TLR1 and TLR6, TLR2 recognizes bacterial lipoproteins and con-
tributes to the formation of thrombi (16). Several recent studies 
have shown that TLR2 is involved in platelet signal transduction, 
platelet aggregation, adherence to collagen, and formation of 
platelet–neutrophil heterotypic aggregates (16–20). Moreover, 
a procoagulant phenotype of extracellular histone-activated 
platelets driving plasma thrombin generation has been reported 
by Semeraro et al., who suggested potential roles for TLR2 and 
TLR4 in this process (21).
As platelets are anucleate, the role of transcription factors 
downstream of their surface receptors remains unclear, but of 
considerable fascination. The NF-κB signaling machinery is 
present in platelets (22–24), but its role downstream of TLR2 and 
TLR4 remains poorly characterized.
Recent data suggest that NF-κB has unexpected roles in 
regulating non-genomic processes involved in platelet functions 
(13, 14, 22, 23, 25) and show that NF-κB inhibitors affect platelet 
functions suggesting different effects of the NF-κB machinery in 
platelets (23, 25).
The innate immune system senses proteolytic enzymes gener-
ated during infection through a family of classical PRRs, such 
as TLRs, and “non-classical” PRRs, for example, PARs (26, 27). 
TLR4 engagement has been investigated in several ways [includ-
ing by ourselves (6, 12, 15, 28–30)]. The aim of our study was to 
compare the effects of TLR2 stimulation on several protein phos-
phorylation processes and to link these effects to platelet alpha 
granule protein and serotonin release. To achieve this goal, we 
compared engagement of TLR2 and the classical thrombin recep-
tor, protease activated receptor 1 (PAR1), on platelet function.
MaTerials anD MeThODs
Platelet Preparation and stimulation
Peripheral blood was collected from healthy donors in 
endotoxin-free 3.2% sodium citrate tubes (Vacutainer®, Becton 
Dickinson, San Jose, CA, USA) within the French National 
Blood Establishment fulfilling the national principles of ethics 
and the regulatory requirements. Platelet-rich plasma (PRP) was 
prepared as described previously (15).
Platelet-rich plasma (3  ×  108  platelets/ml) were incubated 
for 30  min at room temperature (RT) with the anti-human 
FcγRII monoclonal antibody (MoAb) IV.3 (100 µg/ml; StemCell 
Technologies, Grenoble, France) in order to saturate free 
FcγRII sites and block any FcγRII engagement (30, 31). Next, 
platelets were stimulated with the TLR2 ligand Pam3CSK4 
(Cayla-Invivogen, Toulouse, France; 1–100 µg/ml, 120 min, RT) 
in the absence or presence of either one or two anti-human TLR2 
blocking MoAbs, clone TL2.1 (8 µg/ml, 30 min, RT; Imgenex, San 
Diego, CA, USA), and clone B4H2 (8 µg/ml, 30 min, RT; Cayla-
Invivogen) or with an irrelevant specificity MoAbs IgG2a (BD 
Biosciences, Le Pont de Claix, France) control (16). Thrombin 
receptor activator peptide (TRAP; 50  µg/ml; Sigma-Aldrich, 
Saint Quentin Fallavier, France), an agonist of PAR1, was used 
as a positive control.
Platelet Phosphoprotein Profile
pNF-κB (phosphorylated NF-κB at S536 and S468 on p65 
subunit) and total p65 subunit levels in extracts from stimulated 
versus non-stimulated platelets were determined by enzyme-
linked immunosorbent assays (ELISA). pNF-κB (assay sensitiv-
ity = 0.5 µg nuclear extract/well) was detected using a transcription 
factor ELISA kit (Active Motif), as previously described (32). 
Protein phosphorylation of ERK (pT185/pY187), p38 (pT180/
pY182), and Akt (pS473) was determined using the 9-plex 
Multi-Pathway Magnetic Bead Panel (Millipore #46-680MAG, 
Amsterdam, Netherlands) following the manufacturer’s instruc-
tions with the Median Fluorescence Intensity measured by the 
Luminex System.
Flow cytometry and Western Blot
Expression of TLR2 on the platelet surface was determined by 
flow cytometry analysis of all events positive for CD41, a char-
acteristic platelet surface marker. Platelets were labeled with a 
PE-conjugated anti-human TLR2 MoAb (Imgenex) or CD62P 
MoAb (BD Biosciences). Positive events were recorded with a 
FACSCalibur (BD Biosciences) flow cytometer and analyzed with 
CELL QUEST PRO software from BD Biosciences.
Western blot analysis of the expression of TLR2 (3  µg/
ml; Imgenex), MyD88 (3  µg/ml, Santa Cruz Biotechnology), 
NFκB p65 (1  µg/ml; Santa Cruz Biotechnology), histone H3 
(diluted 1/1,000; Abcam), or α-tubulin (200 ng/ml; Santa Cruz 
Biotechnology) was prepared as described previously (28).
enzyme-linked immunosorbent assay for 
soluble Factors in Platelet supernatants
The levels of soluble cytokines sCD62P, RANTES, PF4, and 
sCD40L were measured in triplicate from aliquots of unstimu-
lated (control) and TLR2 ligand-stimulated platelets using 
specific ELISAs (R&D Systems Europe Ltd., Lille, France or 
Abcyss, Paris, France). The serotonin levels were measured by 
competitive ELISA according to the manufacturer’s instructions 
(IBL Immuno-Biological Laboratories, Hamburg, Germany) as 
previously described (33).
analysis of signaling Pathway activation
Platelets were pre-incubated with various concentrations of the 
non-reversible inhibitor of NF-κB, Bay 11-7082 (2 μM) (Sigma-
Aldrich) or Ro 106-9920 (4 μM) (Tocris Bioscience), for 60 min 
at 37°C (23). Platelets were then stimulated with Pam3CSK4 
or TRAP in the presence or absence of an anti-human TLR2 
blocking MoAb to detect NF-κB signal modulation. Platelet 
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supernatants were collected to determine soluble factors levels 
as outlined above.
statistical analysis
All values are reported as mean ± SD. Almost all measurements 
were non-normally distributed. Non-normally distributed data 
were analyzed using non-parametric tests: Mann–Whitney U 
test. Results are given as means with medians with ranges (non-
parametric tests). Statistical test differences were considered 
significant if P values were less than 0.05.
resUlTs
Platelets express components of the 
Tlr2 signaling complex
We first tested for the expression of TLR2 on the surface of 
human blood platelets and the presence of its potential down-
stream signaling machinery. TLR2 is expressed on the surface 
of resting platelets, as shown by flow cytometry (Figure S1 in 
Supplementary Material), at a mean percentage of 30.1 ± 3.76%. 
Supporting this finding from others (20), we observed that activa-
tion of human platelets with TRAP did not significantly affect the 
baseline expression of TLR2; TRAP cannot thus be ascribed as 
over regulating TLR2 expression.
Western-blotting analysis (Figure S1 in Supplementary 
Material) confirmed not only the expression of TLR2 but also, 
as expected, MyD88 and NF-κB in human platelets (16, 19, 22, 
23, 25, 34). The mononuclear cell level in platelet preparations 
was undetectable, as determined by flow cytometry (15). The 
nuclear marker histone H3 was also undetectable in our platelet 
preparation (28), consistent with the absence of nuclear factors 
originating from potential contaminating nucleated cells. Taken 
together, these data support that a significant population of rest-
ing platelets express TLR2 on their surface and have the potential 
downstream effectors to mediate TLR2 signaling.
effect of Tlr2 and Par1 stimulation on 
Platelet Phosphoprotein Profiles
In addition to nuclear translocation, the phosphorylation of the 
p65 subunit of NF-κB on specific serine residues impacts its 
activity. In particular, the phosphorylation of serine 536 (S536) 
and serine 468 (S468) are important for p65-induced cellular 
responses (35). We first tested whether platelet activation by 
TRAP (0–120 min) induced the phosphorylation of the p65 at 
residues S536 and S468. As shown in Figures 1A,C, while total 
p65 protein levels remained stable (data not shown), there was 
a rapid and significant increase in S536 and S468 phosphoryla-
tion following the addition of TRAP. The phosphorylation was 
dose-dependent, becoming detectable between 50 and 250  ng/
ml of TRAP (data not shown). The maximal phosphorylation 
of both S536 (Figure 1A) and S468 (Figure 1C) was observed 
at 30  min of stimulation. Thereafter, phosphorylation levels 
decreased to near basal levels by 90  min, but had increased 
again at 120 min, suggesting the existence of a second wave of 
phosphorylation (Figures 1A,C). Oscillatory dynamics of NF-κB 
nuclear translocation and phosphorylation has been described in 
nucleated eukaryotic cells (36). To our knowledge, this has not 
been reported previously for anucleate cells, such as platelets. 
Interestingly, when human platelets were stimulated with the 
TLR2 agonist Pam3CSK4 (100 µg/ml), the level of S536 phospho-
rylation (Figure 1B) and S468 (Figure 1D) remained low until 
30 min and then significantly increased until the end of the time 
course (120 min).
Because Akt, P38, and ERK1/2 are known to affect the 
modulation of platelet function and several data support a strong 
mechanistic-link between the NF-κB, Akt, P38, and ERK1/2 
pathways (37–41), we analyzed the effect of PAR1 or TLR2 stimu-
lation on these platelet phosphoprotein profiles (Figures 1E–J). 
Platelets were exposed to TRAP (50  µg/ml) or PAM3CSK4 
(100 µg/ml) for increased times (0–120 min), and these intracel-
lular signaling factors were evaluated. First, we demonstrate that 
phosphorylation levels of Akt (pS473), p38 (pT180/Y182) and 
ERK1/2 (pT185/Y187) change over time in response to stimula-
tion by either TRAP or Pam3CSK4 (Figures 1E–J). Second and 
in contrast to our findings for p65 phosphorylation, TRAP and 
Pam3CSK4 elicit similar patterns of phosphorylation for Akt 
(Figures 1E,F), p38 (Figures 1G,H), and ERK1/2 (Figures 1I,J), 
although the kinetics of phosphorylation are distinct for each 
phosphoprotein. Maximal phosphorylation levels are observed 
at 90, 120 and 30 min, respectively. Overall, these results demon-
strate that a highly regulated protein phosphorylation network 
exists in human platelets.
Platelet soluble immunomodulatory 
Factors are released after Tlr2 or Par1 
engagement
Following the addition of conventional platelet agonists, such as 
thrombin or collagen, release of cytokines/chemokines occurs 
between 5 and 30  min (42). A titration and time course were 
performed using human platelets collected from healthy donors 
to determine the optimal concentration of Pam3CSK4 platelet 
activation, using sCD62P and RANTES release as end points 
(Figure S2 in Supplementary Material). We, then, monitored 
platelet cytokine/chemokine secretion for 2  h following TLR2 
stimulation by Pam3CSK4 (100  µg/ml). TRAP (50  µg/ml) 
was also used for comparison, as it potently induces platelet 
release of cytokines/chemokines. In contrast to stimulation 
by TRAP, Pam3CSK4 had no significant effect on serotonin 
release (Figure  2A), nor PF4 release (Figure  2B; Figure S6 in 
Supplementary Material). In contrast, Pam3CSK4 stimulation 
significantly increased the production of sCD62P, RANTES, and 
sCD40L (Figures  2C–E, respectively). In contrast, the produc-
tion of each of these mediators was significantly attenuated when 
platelets were pre-incubated for 30 min at RT with an anti-TLR2 
MoAb (Figures 2C–E).
Importantly, to avoid any potential effect of the Fc portion 
of the anti-TLR2 antibody on FcγRIIA, the IV.3 blocking anti-
body was used in our experiments. As shown in Figure S3 in 
Supplementary Material, the addition of IV.3 antibody had no 
effect on platelet secretion. Moreover, there was no significant 
modification of sCD62P, sCD40L, RANTES, and serotonin 
release after stimulation in the presence of isotype-matched, 
FigUre 1 | TraP and toll-like receptor 2 stimulation in platelets induces changes in phosphorylation (ratio stimulated/unstimulated signal). Analysis 
of p65 subunit of NF-κB phosphorylated S536 (a,B) and S468 (c,D), Akt (pS473) (e,F), P38 (pT180/pY182) (g,h), and ERK1/2 (pT185/pY187) (i,J) in platelet 
extracts from TRAP (50 µg/ml) or Pam3CSK4 (100 µg/ml) stimulated versus non-stimulated platelets. The analysis was performed at different times from 0 to 
120 min of stimulation by TRAP (50 µg/ml) (a,c,e,g,i) or Pam3CSK4 (100 µg/ml) (B,D,F,h,J). Data are mean (± SD) of five independent experiments (measured in 
triplicate). *P < 0.05 (Mann–Whitney U test; stimuli versus unstimulated).
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irrelevant specificity MoAbs IgG2a (Figure S4 in Supplementary 
Material). Overall, these results demonstrate that TLR2 trigger-
ing results in the secretion of a set of platelet cytokine/chemokine 
independently of FcγRIIA.
relationship between specific Tlr2 
stimulation and nF-κb Transducer 
Molecules
In nucleated cells, NF-κB p65 is an important downstream effector 
of TLR2 through the adapter protein MyD88 followed by NF-κB 
triggering of inflammatory cytokine production. To determine 
whether NF-κB is involved in the effects of TLR2 in platelets, we 
used an inhibitor of NF-κB suitable for in vitro studies (Figure 3). 
This compound is a highly selective and widely used irreversible 
inhibitor of NF-κB that impairs IκBα phosphorylation (23, 43). 
Interestingly, the release of sCD62p, RANTES, and sCD40L 
following TLR2 engagement by Pam3CSK4 was decreased to 
almost background levels in the presence of this NF-κB inhibi-
tor (Figures 3A,C,E,G). Similar results were obtained following 
stimulation with TRAP (Figures  3B,D,F,H), suggesting that 
NF-κB is not exclusively required downstream of TLR2 to medi-
ate cytokine secretion, but is also important downstream of the 
stimulation of PAR1. We observed a significant (# P <  0.05) 
decrease of the release of sCD62p, RANTES, and sCD40L follow-
ing TRAP and Pam3CSK4 stimulation when comparing stimu-
lated platelets without inhibitor (BAY 11-7082 or Ro 106-9920) 
versus stimulated in the presence of inhibitor (BAY 11-7082 or 
Ro 106-9920). Using an inhibitor of NF-κB suitable for in vitro 
studies BAY 11-7082 or Ro 106-9920 showed similar results. In 
contrast to TRAP, which induced platelet serotonin release, as 
expected, Pam3CSK4 stimulation did not (Figure 3G). Although 
NF-κB inhibition by BAY-11-7082 or Ro 106-9920 decreased both 
the basal level of serotonin and the amount of serotonin secreted 
FigUre 2 | Platelets release soluble immunomodulatory factors following toll-like receptor (Tlr) 2 or protease activated receptor 1 engagement. 
Platelet serotonin, sCD62P, RANTES, and sCD40L are released by platelets stimulated by TRAP (50 µg/ml) or Pam3CSK4 (100 µg/ml) with (w) or without (w/o) 
anti-human TLR2 blocking monoclonal antibody (MoAb). Platelets were pre-treated (20 min, room temperature) with anti-human FcγRII MoAb IV.3 and 
incubated with TRAP or Pam3CSK4 for 120 min. The levels of serotonin (a), PF4 (B), sCD62P (c), RANTES (D), and sCD40L (e) were quantified by enzyme-
linked immunosorbent assays (measured in triplicate). Background levels were subtracted from the values shown. Data are mean ± SD (n = 5 experiments, 
measured in triplicate) and are expressed as picograms per milliliter (3 × 108 unit—sCD62P, RANTES, and sCD40L) or as micrograms per milliliter 
(3 × 108 unit—serotonin). The soluble factors values shown are deduced from background levels. *P < 0.05 (Mann–Whitney U test; stimuli versus unstimulated). 
Anti-human TLR2 blocking MoAb (α-TLR2) was used at a concentration of 8 µg/ml. #P < 0.05 (Mann–Whitney U test; stimuli w anti-TLR2 block versus stimuli 
w/o anti-TLR2 block).
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FigUre 3 | continued
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FigUre 3 | continued 
nF-κB inhibition attenuates toll-like receptor 2 and protease activated receptor 1 stimulated mediator release. Serotonin, sCD62P, RANTES, and 
sCD40L secretion levels from platelets stimulated by Pam3CSK4 (100 µg/ml) (a,c,e,g) or TRAP (50 µg/ml) (B,D,F,h) with (w) or without (w/o) the inhibitor of NF-κB 
(BAY 11-7082). Platelets were pre-treated (20 min, room temperature) with anti-human FcγRII monoclonal antibody IV.3 and incubated with inhibitor and stimulators 
as described in Section “Materials and Methods.” Levels of sCD62P (a,B), RANTES (c,D), sCD40L (e,F), and serotonin (g,h) were quantified by enzyme-linked 
immunosorbent assays (measured in triplicate). Background levels have been subtracted and the data (mean ± SD; n = 10 experiments, measured in triplicate) are 
expressed in picograms per milliliter. *P < 0.05; Mann–Whitney U test, unstimulated without inhibitor (BAY 11-7082) versus stimulated without inhibitor (BAY 
11-7082) or unstimulated in the presence of inhibitor (BAY 11-7082, 2 μM) versus stimulated in the presence of inhibitor (BAY 11-7082, 2 μM). #P < 0.05 (Mann–
Whitney U test); stimulated without inhibitor (BAY 11-7082) versus stimulated in the presence of inhibitor (BAY 11-7082, 2 μM).
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upon TRAP activation, it did not significantly affect the ability of 
TRAP to stimulate serotonin secretion (4.45-fold increase in the 
absence of BAY-11-7082 versus 5.35-fold increase in the presence 
of BAY-11-7082) (Figure 3H).
DiscUssiOn
Toll-like receptors expressed by various cell types are now well 
recognized as sentinels of the innate immune system, keeping 
vigilance against invading pathogens (44).
Platelets express several functional TLRs, such as TLR1, TLR2, 
TLR4, TLR7, and TLR9 (6, 20, 45–47). Recently, Tunjungputri 
et al. (48) demonstrated an association with an increase in pro-
inflammatory cytokines in blood exposed to Pam3CSK4, but 
a decrease in these cytokines in blood exposed to LPS. These 
findings indicate that platelets differentially modulate TLR2- and 
TLR4-mediated cytokine responses of PBMC. We tested for 
platelet activation markers and sCD62P release following TLR2-, 
4-, 7-, and 9-stimulation, and we evidenced different behaviors of 
platelets depending on the type of TLR that was engaged (Figure 
S5 in Supplementary Material). Our experimental unpublished 
data (Figure S5 in Supplementary Material) suggest that platelet 
TLR2, 3, 4, 7, and 9 are functionally active in inducing sCD62P 
in response to their specific ligands, although the effect on the 
soluble CD62P is differential. These data suggest that platelets 
have the capacity to sense external signals differentially through 
pathogen recognition receptors and adjust the innate immune 
response appropriately for pathogens exhibiting different types 
of “danger” signals.
Human platelets express TLR1 (7, 16) and Pam3CSK is a 
synthetic TLR2/TLR1 agonist, and therefore, we cannot exclude 
that TLR1 play a role in our model. Nevertheless, Blair et al. (16) 
demonstrate that neutralization of TLR2 significantly reduced 
Pam3CSK4-induced platelet aggregation and TLR1 inhibition 
also reduced aggregation, although not as effectively as TLR2 
blockage.
Recent reports demonstrate that, despite being anucleate, 
platelets express a number of transcription factors, including 
the NF-κB transcription factor family (1, 23, 25, 49), retinoic 
X receptor and peroxisome proliferator-activated receptors 
(PPARγ and β/δ) (50, 51). In the present study, we investigated 
pathways considered essential for inflammatory cytokine pro-
duction downstream of TLR2 stimulation (52) and found an 
important and new contribution by NF-κB in human platelets. 
In particular, we have demonstrated the differential mobilization 
of the NF-κB pathway following exposure of platelets to ligands 
of innate immunity receptors (Pam3CSK4 for TLR2) compared 
to ligands of the thrombotic stimulation (TRAP for PAR1). In 
eukaryotic cells, the transcription of target genes depends on 
oscillation persistence, involving cycles of RelA (p65) phospho-
rylation and dephosphorylation (36). Interestingly, changes in 
platelet p65 phosphorylation following TRAP stimulation were 
observed. The presence and non-genomic functions of NF-κB 
family members have been demonstrated by several groups 
(1, 23, 25, 38, 43, 53). Importantly, several reports suggest that 
platelets contain an intact, functional, and complete NF-κB 
pathway. Further, PAR1 has a lower threshold for activation by 
thrombin than PAR4. PAR1 activation typically induces a rapid, 
but transient spike in calcium, while PAR4 activation involves 
a more sustained response, suggesting overlapping, but distinct 
roles for these receptors. These data reveal a novel and distinct 
signaling pathway for PAR1 and PAR4 receptors, although 
both converge on NF-κB signaling. Taken together, these data 
present compelling evidence that NF-κB plays an important, 
albeit complex, role in platelet activation. Nevertheless, Lannan 
et  al. (1) described that thrombin signaling through PAR1 in 
human platelets is mostly independent of NF-κB. These findings 
highlight the complexity of biological responses in platelet sign-
aling. As with eukaryotic cells, computational models will prove 
to be useful in deciphering the complex signaling networks 
found in platelets. This study focused on NF-κB modulation 
concerning platelet activation in response to PAM3CSK4 and/
or TRAP. However, the inhibition of NF-κB also affects platelet 
activation in response to other agonists as can be found in other 
reports (43, 53). Two specific unrelated inhibitors of NF-κB 
activation, BAY 11-7082 and Ro 106-9920, reduced PAC-1 and 
fibrinogen binding to integrin αIIbβ3 and restricted platelet 
spreading on immobilized fibrinogen. Both inhibitors impaired 
aggregation mediated by ADP, epinephrine, collagen, or throm-
bin, but not arachidonic acid. ATP release, TXB2 formation, 
CD62P expression, ERK phosphorylation, and cPLA2 activity 
stimulated by thrombin were reduced in BAY 11-7082- or Ro 
106-9920-treated platelets (43). Moreover, platelet stimulation 
with Pam3CSK4 or LPS resulted in IκBα degradation and p65 
phosphorylation. These responses were suppressed by TLR2 
and 4 blocking. Aggregation, fibrinogen binding, and ATP and 
vWF release were triggered by Pam3CSK4. LPS did not induce 
platelet responses per  se, except for vWF release, but it did 
potentiate thrombin-induced aggregation, fibrinogen binding 
and ATP secretion. Pam3CSK4, but not LPS, induced CD62P 
and CD40L expression and mixed aggregate formation. All of 
these responses, except for CD40L expression, were inhibited in 
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platelets treated with the NF-κB inhibitors BAY 11-7082 or Ro 
106-9920 (53).
There is indication that α-granule subpopulations can be 
identified on the basis of morphology, cargo type, and response 
to agonists (54). Contrary to Berg et al. (55) who described that 
Pam3CysSer(Lys)4, another lipopeptide analog of the NH2-
terminus of bacterial lipoprotein used in our model, led to the 
aggregation of platelets and induced the secretion of serotonin 
with an effectiveness similar to thrombin. Here, we show that 
contrary to stimulation by TRAP, Pam3CSK4 had no significant 
effect on serotonin and PF4 release. In contrast, Pam3CSK4 
stimulation highly increased the production of RANTES in the 
supernatant of PRP. Koenen et al. have shown that disruption of 
PF4-RANTES heterodimers by high affinity peptide ligands can 
slow the development of atherosclerotic plaque development in 
murine models of vascular disease (56). In addition, our results 
confirm that platelet secretion of selected immunomodula-
tory factors may be an important inflammatory-regulating 
mechanism.
In platelets, NF-κB/I-κB proteins have been described to 
function independently of gene regulation; after activation, IκB is 
phosphorylated and degraded (22). Recent new evidence suggests 
a potential novel pathway of platelet regulation by NF-κB, linked 
to key platelet responses (e.g., platelet spreading, aggregation, clot 
retraction) (23, 25).
Recently, Rivadeneyra et al. (53) described TLR2 and 4 agonists 
trigger platelet activation responses through NF-κB. Our data, 
thus, support the Rivadeneyra data and particularly the modula-
tion of expression of platelet TLR2, as shown concomitantly in 
2005 by our group (6) and the Semple group (20). We too observed 
that platelet TLR2 activation results in the activation of the NF-κB 
pathway. The pNF-κB (phosphorylated NF-κB at S536 and S468 
on p65 subunit) and total p65 subunit levels in extracts from stim-
ulated versus non-stimulated platelets were determined by ELISA 
and not by Western Blot, which allowed us to precisely demon-
strate that p65 S536 and S468 subunits were mobilized. Moreover, 
our data show a process concerning phosphorylation of NF-κB 
in human platelets after TLR2 activation (with Pam3CSK4) and 
PAR-1 (TRAP), which has not previously been demonstrated in 
platelet signaling. Importantly, our findings reported here extend 
the Rivadeneyra data. We demonstrate that Pam3CSK4 or TRAP 
induction of NF-κB-mediated pro-inflammatory responses have 
differential effects with regard to the release of soluble factors 
in platelet supernatants, such as sCD62P, RANTES, PF4, and 
sCD40L, markers of α granule release, and serotonin, a marker 
predominantly present in dense granules. In contrast to stimula-
tion by TRAP, Pam3CSK4 had no significant effect on serotonin 
nor PF4 release. Conversely, Pam3CSK4 stimulation significantly 
increased the production of sCD62P, RANTES, and sCD40L. Our 
findings support the hypothesis that TLR-2 and PAR-1 platelet 
stimulation triggers differential protein mobilization; however, 
further studies exploring physiological conditions are needed to 
draw firmer conclusions regarding this hypothesis.
It has been suggested that platelets selectively release their 
alpha and dense granule content dependent on the environmental 
stimulus. Several in vitro data revealed that different granule sub-
sets are selectively released by specific agonists, as suggested by 
agonist-specific a-granule secretion kinetics (57–60). Similarly, 
Chatterjee et  al. demonstrated that PAR1 stimulation or ADP 
exposure elicited robust release of stromal cell-derived factor1 
and VEGF, but modest release of PF4 or endostatin (61). An 
explanation for these observations is that different cargos are 
segregated into different granule subpopulations. This observa-
tion was correlated with two other publications. Peters et al. (54) 
demonstrated that alpha granule can be distinguished based on 
the VAMP isoforms that they express and that a population of 
granules expressing VAMP-7 physically separated from other 
granule populations during spreading. Van Nispen tot Pannerden 
et al. used cryoelectron tomography to provide a 3-dimensional 
(3D) map of the intracellular membrane organization of human 
platelets and revealed a large heterogeneity in the platelet mem-
brane organization. They concluded that aside from the existence 
of morphologically different alpha-granule subtypes, the 3D 
study demonstrated that high spatial segregation of cargo exists 
within individual alpha-granules (62).
Moreover, recent studies by Starlinger et  al. present clinical 
evidence that the profile of circulating platelet a-granule proteins 
seems to affect postoperative liver regeneration in patients after 
liver resection. They conclude that selective a-granule release 
might modify pathophysiological processes involved in liver 
regeneration (63). Our observations support the concept that 
NF-κB proteins are important in both the pro-thrombotic and 
immunomodulatory functions of platelets. Indeed, NF-κB inhibi-
tion significantly decreased the secretion of serotonin, cytokines, 
and chemokines from platelets stimulated either by Pam3CSK4 
or by TRAP, a PAR1 agonist. This is consistent with studies by 
Malaver et al. who showed that BAY-11-7082 inhibited platelet 
aggregation (43) and by Spinelli et  al. who demonstrated that 
inhibition of I-κB-α phosphorylation by BAY-11-7082 caused 
reversal of fully spread platelets to their original spheroid mor-
phology (23).
Our data also highlight the functional role of the TLR signal-
ing pathway. This is important as platelets interact primarily 
with the vessel endothelium, a tissue that can be inflamed and is 
reactive to pro-inflammatory products originating from platelets 
(64). We recently proposed (30, 65) that platelets employ adaptive 
responses to danger signals, which involve a polarized secretion 
for soluble immunomodulatory factors; NF-κB could orientate 
this. The discovery of non-hemostatic functions for platelets 
continue to increase, and include the role of platelets in infec-
tious and/or inflammatory diseases. Future work is necessary to 
elucidate whether TLR2 (and/or TLR1) activation has a direct 
effect on platelet activation, and to further define the role of 
platelets in innate immune signaling. Importantly, TLR2 (and/or 
TLR1) could represent a potential new target for drug discovery. 
However, in order to develop new pharmaceutical drugs that 
target platelet participation in infectious and/or inflammatory 
disease, a novel role for platelet TLR signaling must be demon-
strated that is independent of prothrombotic pathways.
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